查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
2030 年奈米医学市场预测：按产品类型、模式、适应症、应用和地区进行的全球分析
市场调查报告书
商品编码
1383467

2030 年奈米医学市场预测：按产品类型、模式、适应症、应用和地区进行的全球分析

Nanomedicine Market Forecasts to 2030 - Global Analysis By Product Type (Nanoparticles, Nano Tubes, Nano Devices, Nano Shells and Other Product Types), Modality (Treatment and Diagnostics), Indication, Application and by Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据Stratistics MRC的数据，2023年全球奈米药物市场规模为4.3284亿美元，预计到2030年将达到11.3051亿美元，预测期内年复合成长率为14.7%。

奈米技术在医疗保健中的创新应用被称为奈米医学。它利用了 10-9 m 奈米尺度材料的特性，从生物、化学和物理角度来看，这些特性通常与较大尺寸的相同材料不同。此外，由于人体内的许多生物过程都是在奈米尺度上进行的，因此奈米材料和奈米颗粒可以克服其预期输送系统的障碍，并可用于血液以及器官、细胞和组织内。不同程度地含有小蛋白质和DNA。

根据美国美国的死亡病例是死于心臟病。

慢性病增加

随着糖尿病、癌症、心血管疾病和神经退化性疾病等慢性病的全球负担日益加重，迫切需要先进的医疗解决方案。此外，奈米医学在提供针对性干预、早期疾病检测和更有效治疗方面的潜力满足了越来越多患有这些慢性疾病的患者的需求。

开发价高

由于这些技术非常复杂，开发奈米医学领域的新产品需要大量资金。此外，设计和测试奈米级药物传输系统、诊断设备和奈米颗粒都是研发过程的一部分，这可能是资源密集的。对于新兴企业和小型企业来说，高昂的开发成本可能会成为进入障碍。

药物给药的进展

奈米医学驱动的药物传输系统的不断进步为最佳化药物给药提供了前景。透过减少给药次数并提供受控和持续的药物释放，这些创新有可能提高患者的医嘱遵从性和依从性。此外，这不仅提高了患者满意度，还提高了治疗效果，特别是在治疗慢性疾病时。

社会和道德问题

社会对医学奈米技术的接受和认识可能会受到有关资料安全、隐私和奈米设备潜在滥用的道德担忧的影响。此外，为了获得公众信任并克服对奈米医学的抵制，需要解决这些道德问题并负责任地进行开发。

COVID-19 的影响：

奈米医学市场受到了 COVID-19大流行的各种影响。这场大流行凸显了对尖端医疗程序、治疗方法和免疫接种的需求，但它也扰乱了供应链，推迟了研究倡议，并将资金转移到了大流行应对工作上。从积极的一面来看，新的药物传输方法、奈米级 COVID-19 疫苗和诊断都可以透过奈米医学实现。然而，由于大流行的经济影响，一些奈米医学倡议，特别是在学术和研究领域，面临资金挑战。

预计心血管疾病领域在预测期内将是最大的。

预计心血管疾病将占据市场的最大份额。心臟和血管疾病，包括冠状动脉疾病、高血压、郁血性心臟衰竭和心律不整，都被认为是心血管疾病。全世界心血管疾病的高盛行率及其对公共卫生的重大影响是该领域受到关注的原因。此外，药品、医疗设备、诊断工具和介入手术都是心血管疾病市场的一部分。新治疗方法的开拓、心血管手术和介入性心臟病学的进步都是推动这一市场扩张的主要因素。

预测期内，再生医学领域预估复合年复合成长率最高

年复合成长率最高的市场是再生医学领域。替代、再生和修復患病或受损组织和器官的治疗方法方法和方法的开发被称为再生医学。这包括使用生物材料、组织工程和干细胞疗法来支持自然癒合过程。此外，人口高龄化、慢性病的增加以及可治疗从神经系统疾病到心血管疾病等多种疾病的新疗法的需求，是高年复合成长率的主要驱动力。

比例最高的地区：

由于完善的医疗基础设施、高昂的医疗成本、活跃的高龄化多种因素，预计北美将占据全球医疗保健市场的最大份额。此外，该地区尖端的医疗技术、製药公司、一流的研究机构以及对创新的关注使其成为医疗保健领域的主要参与者。美国和加拿大在医疗进步和医疗保健服务方面处于领先地位，北美对新出现的医疗保健挑战和医疗保健疾病的积极应对进一步巩固了其在全球医疗保健市场的领导者地位。我正在这样做。

复合年复合成长率最高的地区：

在全球医疗保健市场中，亚太地区的年复合成长率最高。推动这一巨大增长的因素有很多，包括该地区人口的不断增长、医疗保健意识的提高、经济的加速发展以及医疗保健服务的普及。此外，亚太地区吸引了製药公司和医疗技术供应商的大量投资，使其成为临床试验和医学研发的中心。因此，该地区在医疗保健基础设施、新治疗方法和数数位医疗解决方案方面取得了快速进步，成为全球医疗保健产业成长和创新的关键催化剂。

免费客製化服务

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 产品分析
  • 应用分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球奈米医学市场：依产品类型

  • 奈米颗粒
    • 金属和金属氧化物奈米颗粒
    • 脂质体
    • 聚合物和聚合物药物缀合物
    • 水凝胶奈米颗粒
    • 树枝状聚合物
    • 无机奈米粒子
  • 奈米管
  • 奈米装置
  • 奈米壳
  • 其他产品类型

第6章全球奈米医学市场：依形式分类

  • 过程
  • 诊断

第7章全球奈米医学市场：依适应症分类

  • 临床肿瘤学
  • 感染疾病
  • 临床循环系统
  • 泌尿系统
  • 眼科
  • 免疫学
  • 心血管疾病
  • 整形外科疾病
  • 神经系统疾病
  • 抗发炎疾病
  • 感染疾病对策
  • 其他适应症

第8章全球奈米医学市场：依应用分类

  • 药物输送
  • 诊断影像
  • 体外诊断
  • 植入
  • 再生医学
  • 疫苗
  • 体外成像
  • 疗法
  • 体内影像
  • 其他用途

第9章全球奈米医学市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东/非洲

第10章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第11章公司简介

  • NanoCarrier Co. Ltd
  • Sanofi SA
  • Leadient BioSciences Inc.
  • Celgene Corporation
  • Abbott Laboratories
  • CombiMatrix Corporation
  • Johnson & Johnson Services Inc
  • Mallinckrodt Pharmaceuticals
  • Nanobiotix
  • Merck & Co., Inc.
  • Nanospectra Biosciences, Inc.
  • Gilead Sciences, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Novavax, Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • GE Healthcare
  • Taiwan Liposome Company Ltd
  • Genzyme Corporation
Product Code: SMRC24315

According to Stratistics MRC, the Global Nanomedicine Market is accounted for $432.84 million in 2023 and is expected to reach $1130.51 million by 2030 growing at a CAGR of 14.7% during the forecast period. The innovative use of nanotechnology in healthcare is known as nanomedicine. It utilizes a material's properties at its nanometric scale of 10-9 m, which are frequently different from the same substance at a larger size in terms of biology, chemistry, and physics. Additionally, because many biological processes in the human body operate on a nanometric scale, nanomaterials and nanoparticles may be able to get past obstacles in the way of their intended delivery systems and interact at different degrees with small proteins or DNA in blood or within organs, cells, and tissues.

According to the Centres for Disease Control and Prevention, one in four fatalities in the United States occurred due to heart disease in 2021.

Market Dynamics:

Driver:

Growing chronic illness incidence

Advanced medical solutions are urgently needed as the burden of chronic diseases, such as diabetes, cancer, cardiovascular disease, and neurodegenerative disorders, is rising globally. Moreover, the potential of nanomedicine to provide targeted interventions, early disease detection, and more effective therapies is in line with the needs of an increasing number of patients suffering from these chronic illnesses.

Restraint:

High price of development

Due to the fact that these technologies are so complex, developing new products in the field of nanomedicine requires large financial outlays. Additionally, the design and testing of nanoscale drug delivery systems, diagnostic instruments, and nanoparticles are all part of the research and development process, which can be resource-intensive. For startups and smaller businesses, this high development cost may be a barrier to entry.

Opportunity:

Advances in drug administration

The ongoing advancement of drug delivery systems driven by nanomedicine presents prospects for optimizing the administration of medication. By lowering dosage frequency and offering controlled, sustained drug release, these innovations may enhance patient adherence and compliance. Furthermore, this improves patient satisfaction as well as the effectiveness of treatment, especially when managing chronic diseases.

Threat:

Social and ethical issues

Public acceptance and perception of nanotechnology in medicine may be impacted by ethical worries about data security, privacy, and possible misuse of nanoscale devices. Moreover, gaining the public's trust and overcoming resistance to nanomedicine require addressing these ethical issues and making sure that development is done responsibly.

COVID-19 Impact:

The market for nanomedicine has been impacted by the COVID-19 pandemic in a number of ways. The pandemic emphasized the need for cutting-edge medical procedures, therapies, and vaccinations, but it also caused supply chain disruptions, postponed research initiatives, and redirected funds toward pandemic response efforts. Positively, new drug delivery methods, COVID-19 vaccines at the nanoscale, and diagnostics were all made possible by nanomedicine. However, some nanomedicine initiatives faced funding difficulties as a result of the pandemic's economic effects, especially in the academic and research sectors.

The Cardiovascular Diseases segment is expected to be the largest during the forecast period

Cardiovascular diseases are predicted to hold the largest share in the market. Heart and blood vessel disorders, including coronary artery disease, hypertension, congestive heart failure, and arrhythmias, are all considered cardiovascular diseases. The high prevalence of cardiovascular diseases worldwide and their substantial impact on public health are the reasons for this segment's prominence. Moreover, pharmaceuticals, medical devices, diagnostic tools, and interventional procedures are all part of the cardiovascular disease market. The development of novel therapies, cardiac surgery advancements, and interventional cardiology has all been major factors in this market's expansion.

The Regenerative Medicine segment is expected to have the highest CAGR during the forecast period

The regenerative medicine segment holds the highest CAGR in the market. Developing treatments and methods to replace, regenerate, or repair diseased or damaged tissues and organs is known as regenerative medicine. It includes the use of biomaterials to support natural healing processes, tissue engineering, and stem cell therapies. Furthermore, the aging population, the rise in chronic illness, and the demand for novel treatments capable of curing a broad spectrum of illnesses, from neurological disorders to cardiovascular diseases, are the main causes of the high compound annual growth rate.

Region with largest share:

Due to a number of factors, including a well-established healthcare infrastructure, high healthcare expenditures, robust research and development activities, and an aging population with greater healthcare needs, North America is predicted to hold the largest share of the global healthcare market. Moreover, the region is a major player in the healthcare sector because of its cutting-edge medical technologies, pharmaceutical companies, top research institutions, and strong emphasis on innovation. With the United States and Canada at the forefront of medical advancements and healthcare services, North America's proactive response to emerging healthcare challenges and diseases further solidifies its position as a leader in the global healthcare market.

Region with highest CAGR:

In the global healthcare market, the Asia-Pacific region has the highest CAGR. Numerous factors, such as the region's expanding population, growing awareness of healthcare, accelerating economic development, and improved access to healthcare services, are driving this amazing growth. Additionally, the Asia-Pacific area has drawn large investments from pharmaceutical firms and suppliers of medical technology, making it a hub for clinical trials, medical research, and development. Consequently, the region is experiencing swift progress in healthcare infrastructure, novel therapies, and digital health solutions, thereby establishing itself as a primary catalyst for growth and innovation in the global healthcare industry.

Key players in the market

Some of the key players in Nanomedicine market include: NanoCarrier Co. Ltd, Sanofi SA, Leadient BioSciences Inc., Sigma-Tau Pharmaceuticals, Inc., Celgene Corporation, Abbott Laboratories, CombiMatrix Corporation, Johnson & Johnson Services Inc, Mallinckrodt Pharmaceuticals, Nanobiotix, Merck & Co., Inc., Nanospectra Biosciences, Inc., Gilead Sciences, Inc., Arrowhead Pharmaceuticals, Inc., Novavax, Inc., Pfizer, Inc., Teva Pharmaceutical Industries Ltd., GE Healthcare, Taiwan Liposome Company Ltd and Genzyme Corporation.

Key Developments:

In October 2023, Janssen Pharmaceuticals, Inc., a Johnson & Johnson Company, announced a development and commercialization agreement with Sanofi for Janssen's extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine program. The lead vaccine candidate is currently being evaluated in the Phase 3 E.mbrace study for the prevention of invasive E. coli disease (IED) in adults aged 60 years and older.

In October 2023, Sanofi announces that it has entered into an agreement with Janssen Pharmaceuticals, Inc. (Janssen), a Johnson & Johnson company, to develop and commercialize the vaccine candidate for extraintestinal pathogenic E. coli (9-valent) developed by Janssen, currently in Phase 3. The agreement brings together Janssen's robust science behind this potential first-in-class product and Sanofi's worldwide manufacturing footprint and recognized world-class expertise in launching innovative vaccines.

In September 2023, Abbott has entered a definitive agreement for the acquisition of Bigfoot Biomedical, which develops smart insulin management systems for individuals with diabetes. Together, the companies have worked on connected diabetes solutions since 2017. Developed by Bigfoot Biomedical, Bigfoot Unity is a smart insulin management system. It features connected insulin pen caps that use integrated continuous glucose monitoring (iCGM) data and healthcare provider instructions.

Product Types Covered:

  • Nanoparticles
  • Nano Tubes
  • Nano Devices
  • Nano Shells
  • Other Product Types

Modalities Covered:

  • Treatment
  • Diagnostics

Indications Covered:

  • Clinical Oncology
  • Infectious Diseases
  • Clinical Cardiology
  • Urology
  • Ophthalmology
  • Immunology
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Neurological Diseases
  • Anti-Inflammatory Diseases
  • Anti-Infective Diseases
  • Other Indications

Applications Covered:

  • Drug Delivery
  • Diagnostic Imaging
  • In vitro Diagnostics
  • Implants
  • Regenerative Medicine
  • Vaccines
  • In-Vitro Imaging
  • Therapeutics
  • In-vivo Imaging
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Nanomedicine Market, By Product Type

  • 5.1 Introduction
  • 5.2 Nanoparticles
    • 5.2.1 Metal & Metal Oxide Nanoparticles
    • 5.2.2 Liposomes
    • 5.2.3 Polymers & Polymer Drug Conjugates
    • 5.2.4 Hydrogel Nanoparticles
    • 5.2.5 Dendrimers
    • 5.2.6 Inorganic Nanoparticles
  • 5.3 Nano Tubes
  • 5.4 Nano Devices
  • 5.5 Nano Shells
  • 5.6 Other Product Types

6 Global Nanomedicine Market, By Modality

  • 6.1 Introduction
  • 6.2 Treatment
  • 6.3 Diagnostics

7 Global Nanomedicine Market, By Indication

  • 7.1 Introduction
  • 7.2 Clinical Oncology
  • 7.3 Infectious Diseases
  • 7.4 Clinical Cardiology
  • 7.5 Urology
  • 7.6 Ophthalmology
  • 7.7 Immunology
  • 7.8 Cardiovascular Diseases
  • 7.9 Orthopedic Diseases
  • 7.10 Neurological Diseases
  • 7.11 Anti-Inflammatory Diseases
  • 7.12 Anti-Infective Diseases
  • 7.13 Other Indications

8 Global Nanomedicine Market, By Application

  • 8.1 Introduction
  • 8.2 Drug Delivery
  • 8.3 Diagnostic Imaging
  • 8.4 In vitro Diagnostics
  • 8.5 Implants
  • 8.6 Regenerative Medicine
  • 8.7 Vaccines
  • 8.8 In-Vitro Imaging
  • 8.9 Therapeutics
  • 8.10 In-vivo Imaging
  • 8.11 Other Applications

9 Global Nanomedicine Market, By Geography

  • 9.1 Introduction
  • 9.2 North America
    • 9.2.1 US
    • 9.2.2 Canada
    • 9.2.3 Mexico
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 Italy
    • 9.3.4 France
    • 9.3.5 Spain
    • 9.3.6 Rest of Europe
  • 9.4 Asia Pacific
    • 9.4.1 Japan
    • 9.4.2 China
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 New Zealand
    • 9.4.6 South Korea
    • 9.4.7 Rest of Asia Pacific
  • 9.5 South America
    • 9.5.1 Argentina
    • 9.5.2 Brazil
    • 9.5.3 Chile
    • 9.5.4 Rest of South America
  • 9.6 Middle East & Africa
    • 9.6.1 Saudi Arabia
    • 9.6.2 UAE
    • 9.6.3 Qatar
    • 9.6.4 South Africa
    • 9.6.5 Rest of Middle East & Africa

10 Key Developments

  • 10.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 10.2 Acquisitions & Mergers
  • 10.3 New Product Launch
  • 10.4 Expansions
  • 10.5 Other Key Strategies

11 Company Profiling

  • 11.1 NanoCarrier Co. Ltd
  • 11.2 Sanofi SA
  • 11.3 Leadient BioSciences Inc.
  • 11.4 Celgene Corporation
  • 11.5 Abbott Laboratories
  • 11.6 CombiMatrix Corporation
  • 11.7 Johnson & Johnson Services Inc
  • 11.8 Mallinckrodt Pharmaceuticals
  • 11.9 Nanobiotix
  • 11.10 Merck & Co., Inc.
  • 11.11 Nanospectra Biosciences, Inc.
  • 11.12 Gilead Sciences, Inc.
  • 11.13 Arrowhead Pharmaceuticals, Inc.
  • 11.14 Novavax, Inc.
  • 11.15 Pfizer, Inc.
  • 11.16 Teva Pharmaceutical Industries Ltd.
  • 11.17 GE Healthcare
  • 11.18 Taiwan Liposome Company Ltd
  • 11.19 Genzyme Corporation

List of Tables

  • Table 1 Global Nanomedicine Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Nanomedicine Market Outlook, By Product Type (2021-2030) ($MN)
  • Table 3 Global Nanomedicine Market Outlook, By Nanoparticles (2021-2030) ($MN)
  • Table 4 Global Nanomedicine Market Outlook, By Metal & Metal Oxide Nanoparticles (2021-2030) ($MN)
  • Table 5 Global Nanomedicine Market Outlook, By Liposomes (2021-2030) ($MN)
  • Table 6 Global Nanomedicine Market Outlook, By Polymers & Polymer Drug Conjugates (2021-2030) ($MN)
  • Table 7 Global Nanomedicine Market Outlook, By Hydrogel Nanoparticles (2021-2030) ($MN)
  • Table 8 Global Nanomedicine Market Outlook, By Dendrimers (2021-2030) ($MN)
  • Table 9 Global Nanomedicine Market Outlook, By Inorganic Nanoparticles (2021-2030) ($MN)
  • Table 10 Global Nanomedicine Market Outlook, By Nano Tubes (2021-2030) ($MN)
  • Table 11 Global Nanomedicine Market Outlook, By Nano Devices (2021-2030) ($MN)
  • Table 12 Global Nanomedicine Market Outlook, By Nano Shells (2021-2030) ($MN)
  • Table 13 Global Nanomedicine Market Outlook, By Other Product Types (2021-2030) ($MN)
  • Table 14 Global Nanomedicine Market Outlook, By Modality (2021-2030) ($MN)
  • Table 15 Global Nanomedicine Market Outlook, By Treatment (2021-2030) ($MN)
  • Table 16 Global Nanomedicine Market Outlook, By Diagnostics (2021-2030) ($MN)
  • Table 17 Global Nanomedicine Market Outlook, By Indication (2021-2030) ($MN)
  • Table 18 Global Nanomedicine Market Outlook, By Clinical Oncology (2021-2030) ($MN)
  • Table 19 Global Nanomedicine Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 20 Global Nanomedicine Market Outlook, By Clinical Cardiology (2021-2030) ($MN)
  • Table 21 Global Nanomedicine Market Outlook, By Urology (2021-2030) ($MN)
  • Table 22 Global Nanomedicine Market Outlook, By Ophthalmology (2021-2030) ($MN)
  • Table 23 Global Nanomedicine Market Outlook, By Immunology (2021-2030) ($MN)
  • Table 24 Global Nanomedicine Market Outlook, By Cardiovascular Diseases (2021-2030) ($MN)
  • Table 25 Global Nanomedicine Market Outlook, By Orthopedic Diseases (2021-2030) ($MN)
  • Table 26 Global Nanomedicine Market Outlook, By Neurological Diseases (2021-2030) ($MN)
  • Table 27 Global Nanomedicine Market Outlook, By Anti-Inflammatory Diseases (2021-2030) ($MN)
  • Table 28 Global Nanomedicine Market Outlook, By Anti-Infective Diseases (2021-2030) ($MN)
  • Table 29 Global Nanomedicine Market Outlook, By Other Indications (2021-2030) ($MN)
  • Table 30 Global Nanomedicine Market Outlook, By Application (2021-2030) ($MN)
  • Table 31 Global Nanomedicine Market Outlook, By Drug Delivery (2021-2030) ($MN)
  • Table 32 Global Nanomedicine Market Outlook, By Diagnostic Imaging (2021-2030) ($MN)
  • Table 33 Global Nanomedicine Market Outlook, By In vitro Diagnostics (2021-2030) ($MN)
  • Table 34 Global Nanomedicine Market Outlook, By Implants (2021-2030) ($MN)
  • Table 35 Global Nanomedicine Market Outlook, By Regenerative Medicine (2021-2030) ($MN)
  • Table 36 Global Nanomedicine Market Outlook, By Vaccines (2021-2030) ($MN)
  • Table 37 Global Nanomedicine Market Outlook, By In-Vitro Imaging (2021-2030) ($MN)
  • Table 38 Global Nanomedicine Market Outlook, By Therapeutics (2021-2030) ($MN)
  • Table 39 Global Nanomedicine Market Outlook, By In-vivo Imaging (2021-2030) ($MN)
  • Table 40 Global Nanomedicine Market Outlook, By Other Applications (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.